Vicebio
Vicebio is a biopharmaceutical company focused on developing next-generation respiratory virus vaccines using its proprietary Molecular Clamp technology. The company aims to deliver broad protection, ready-to-use formulations, and high manufacturability for vaccines targeting life-threatening respiratory viruses. With a science-driven approach and a robust pipeline, Vicebio is advancing innovative solutions to global health challenges.
Industries
Nr. of Employees
small (1-50)
Products
Bivalent recombinant subunit vaccine candidate targeting RSV and hMPV (Phase 1)
A bivalent recombinant subunit vaccine candidate formulated to elicit protective immunity against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV); advanced into Phase I clinical testing with enrollment of older adults.
Trivalent recombinant vaccine candidate targeting RSV, hMPV and PIV3 (preclinical/development)
A trivalent vaccine formulation under development intended to provide simultaneous protection against RSV, hMPV and Parainfluenza Virus Type 3 (PIV3); intended for high manufacturability and ready-to-use presentation.
Platform for prefusion-stabilized recombinant glycoprotein vaccine candidates
A platform approach to design and produce prefusion-stabilized recombinant glycoprotein antigens applicable across multiple respiratory (and other) viruses to enable multivalent vaccine formulation and scalable manufacture.
Bivalent recombinant subunit vaccine candidate targeting RSV and hMPV (Phase 1)
A bivalent recombinant subunit vaccine candidate formulated to elicit protective immunity against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV); advanced into Phase I clinical testing with enrollment of older adults.
Trivalent recombinant vaccine candidate targeting RSV, hMPV and PIV3 (preclinical/development)
A trivalent vaccine formulation under development intended to provide simultaneous protection against RSV, hMPV and Parainfluenza Virus Type 3 (PIV3); intended for high manufacturability and ready-to-use presentation.
Platform for prefusion-stabilized recombinant glycoprotein vaccine candidates
A platform approach to design and produce prefusion-stabilized recombinant glycoprotein antigens applicable across multiple respiratory (and other) viruses to enable multivalent vaccine formulation and scalable manufacture.
Expertise Areas
- Multivalent vaccine development
- Prefusion-stabilized recombinant glycoprotein vaccines
- CMC and GMP manufacturing scale-up for biologics
- Phase I clinical trial management and execution
Key Technologies
- Prefusion-stabilized recombinant viral glycoprotein design
- Protein trimerization/stabilization tags
- Recombinant protein expression and high-yield purification
- Subunit vaccine platform